124 related articles for article (PubMed ID: 34596147)
1. Baseline neutrophil-lymphocyte ratio is associated with outcomes in patients with castration-resistant prostate cancer treated with Docetaxel in South China.
Jiang ZG; Liao SG
Medicine (Baltimore); 2021 Oct; 100(39):e27361. PubMed ID: 34596147
[TBL] [Abstract][Full Text] [Related]
2. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of neutrophil-to-lymphocyte ratio in castration resistant prostate cancer: Single-centre study of Nigerian men.
Bello JO; Olanipekun OO; Babata AL
Niger J Clin Pract; 2019 Apr; 22(4):511-515. PubMed ID: 30975955
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
[TBL] [Abstract][Full Text] [Related]
5. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
6. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A
Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
[TBL] [Abstract][Full Text] [Related]
8. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel.
Sümbül AT; Sezer A; Abalı H; Köse F; Gültepe I; Mertsoylu H; Muallaoğlu S; Özyılkan Ö
Int Urol Nephrol; 2014 Aug; 46(8):1531-5. PubMed ID: 24526335
[TBL] [Abstract][Full Text] [Related]
10. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
12. Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.
Conteduca V; Crabb SJ; Jones RJ; Caffo O; Elliott T; Scarpi E; Fabbri P; Derosa L; Massari F; Numico G; Zarif S; Hanna C; Maines F; Joyce H; Lolli C; De Giorgi U
PLoS One; 2016; 11(7):e0158952. PubMed ID: 27434372
[TBL] [Abstract][Full Text] [Related]
13. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
Chong W; Zhang Z; Luo R; Gu J; Lin J; Wei Q; Li B; Myers R; Lu-Yao G; Kelly WK; Wang C; Yang H
BMC Cancer; 2021 Jun; 21(1):655. PubMed ID: 34078304
[TBL] [Abstract][Full Text] [Related]
14. Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio.
Koo KC; Lee JS; Ha JS; Han KS; Lee KS; Hah YS; Rha KH; Hong SJ; Chung BH
World J Urol; 2019 Nov; 37(11):2375-2384. PubMed ID: 30734074
[TBL] [Abstract][Full Text] [Related]
15. The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer.
Tatenuma T; Kawahara T; Hayashi N; Hasumi H; Makiyama K; Nakaigawa N; Kishida T; Miyoshi Y; Yao M; Uemura H
Biomed Res Int; 2019; 2019():2535270. PubMed ID: 31781602
[TBL] [Abstract][Full Text] [Related]
16. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients.
Stangl-Kremser J; Mari A; Suarez-Ibarrola R; D'Andrea D; Korn SM; Pones M; Kramer G; Karakiewicz P; Enikeev DV; Glybochko PV; Briganti A; Shariat SF
Urol Oncol; 2020 Jun; 38(6):600.e9-600.e15. PubMed ID: 31953003
[TBL] [Abstract][Full Text] [Related]
17. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
Lorente D; Mateo J; Templeton AJ; Zafeiriou Z; Bianchini D; Ferraldeschi R; Bahl A; Shen L; Su Z; Sartor O; de Bono JS
Ann Oncol; 2015 Apr; 26(4):750-755. PubMed ID: 25538172
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H
Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682
[TBL] [Abstract][Full Text] [Related]
19. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.
Man YN; Chen YF
Int Urol Nephrol; 2019 Dec; 51(12):2189-2199. PubMed ID: 31456101
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.
Mehra N; Sharp A; Lorente D; Dolling D; Sumanasuriya S; Johnson B; Dearnaley D; Parker C; de Bono J
Clin Genitourin Cancer; 2017 Dec; 15(6):678-684.e1. PubMed ID: 28606735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
